This bill addresses the critical and growing problem of antimicrobial resistance, often referred to as 'superbugs,' where bacteria and other germs evolve to resist existing medications. This resistance makes common infections harder to treat, leading to longer hospital stays, higher medical costs, and increased deaths. Currently, there's little financial incentive for drug companies to develop new antimicrobials because these drugs are often reserved for severe cases to prevent further resistance, resulting in lower sales volumes and less profit.

If this bill becomes law, it would create a guaranteed financial return for companies, encouraging them to invest in this crucial, but often unprofitable, research area. This could lead to a pipeline of new, effective drugs for future health crises. If it doesn't become law, the current trend of declining antimicrobial development is likely to continue, leaving the nation increasingly vulnerable to untreatable infections and making future pandemics or public health emergencies much harder to manage.